Shionogi & Co

Shionogi & Co Intangible Assets

The Intangible Assets of Shionogi & Co (4507.T) as of Nov 2, 2026 is 143.65 B JPY. In the previous year, Intangible Assets was 117.62 B JPY — a change of 22.13% (higher).

Intangible Assets

143.65 BJPY

YoY

22.13%

Last updated:

Intangible Assets of Shionogi & Co is 2025 143.65 B JPY. Intangible Assets of Shionogi & Co was 2024 117.62 B JPY. It decreases by 22.13% higher compared to the previous year.

The Shionogi & Co Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2018
42.21 B JPY
Jan 1, 2019
47.80 B JPY
Jan 1, 2020
51.71 B JPY
Jan 1, 2021
76.56 B JPY
Jan 1, 2022
81.22 B JPY
Jan 1, 2023
96.31 B JPY
Jan 1, 2024
117.62 B JPY
Jan 1, 2025
143.65 B JPY
The Shionogi & Co Intangible Assets history
YEARIntangible AssetsYoY
143.65 BJPY+22.13%
117.62 BJPY+22.13%
96.31 BJPY+18.57%
81.22 BJPY+6.09%
76.56 BJPY+48.07%
51.71 BJPY+8.16%
47.80 BJPY+13.26%
42.21 BJPY-15.53%
49.97 BJPY+90.12%
26.28 BJPY-9.54%
29.06 BJPY-2.97%
29.95 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shionogi & Co Stock analysis

What does Shionogi & Co do? The company Shionogi & Co Ltd is a Japanese pharmaceutical company based in Osaka. It was founded in 1878 and has since become a significant player in the industry. It currently employs over 6,000 employees worldwide and is listed on the Tokyo Stock Exchange. Shionogi is divided into several business segments that offer different products and services. The largest segment is the pharmaceutical division, which specializes in the development and marketing of drugs. The company has strong expertise in infectious diseases, pain management, and oncology, and operates in many countries worldwide. One flagship product is the antibiotic Cefditoren, used to treat various bacterial infections. In addition to the pharmaceutical division, Shionogi is also active in other areas. For example, the company offers diagnostic and laboratory services, operating multiple labs in Japan and other countries. Another business segment is the production and marketing of nutritional supplements, sold in Japan, China, and the USA. Shionogi's business model is based on extensive research and development, as well as strong brand positioning. The company invests a significant portion of its revenue each year in the research and development of new drugs and better treatment options for existing diseases. Thanks to the high quality of its products and strong brand, the company has a loyal customer base. In recent years, Shionogi has focused on international expansion opportunities and has expanded its activities in various regions. For example, it has partnered with US pharmaceutical company Purdue Pharma to develop and market a novel pain medication. Shionogi's annual revenue is around 1.5 billion euros. The company is particularly strong in Japan and other Asian countries, but is also active in the US and Europe. In the coming years, Shionogi aims to further expand its international business and solidify its position as a significant player in the industry. Key focuses will be on the launch of new products and finding treatments for previously incurable diseases. Overall, Shionogi is an innovative and successful company that utilizes its expertise in the pharmaceutical industry in various ways. With its dedicated employees and strong brand, it will continue to play an important role in the industry. Shionogi & Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shionogi & Co stock

Intangible Assets of Shionogi & Co is 143.65 B JPY in 2025.

Intangible Assets of Shionogi & Co changed from 117.62 B JPY to 143.65 B JPY, representing a 22.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Shionogi & Co since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Shionogi & Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Shionogi & Co

All Key Metrics — Shionogi & Co